LGG Probiotic for Eczema and Atopic Dermatitis: What the Research Shows About Prevention, Treatment, and the Gut-Skin Axis

Atopic dermatitis is one of the most common chronic conditions of early childhood, affecting roughly one in five children in many high-income countries. For parents looking beyond steroid creams and moisturizers, probiotics are an obvious next stop. The question is whether the evidence supports them, and if so, which strain, in whom, and at what stage.

This article walks through the research on Lactobacillus rhamnosus GG (LGG) in eczema and atopic dermatitis. It is the most studied single probiotic strain in this area. The strongest signal is for primary prevention in high-risk infants. The signal for treating established atopic dermatitis is weaker. We will be direct about both sides.

Atopic Dermatitis and the Gut-Skin Axis

Atopic dermatitis is a chronic inflammatory skin disease characterized by impaired skin barrier function, itch, and a T-helper 2 (Th2) skewed immune response. It often begins in infancy and frequently precedes other atopic conditions, a sequence called the atopic march that runs from eczema to food allergy to asthma and allergic rhinitis. Risk is strongly familial. Children with one atopic parent have roughly double the risk of the general population, and children with two atopic parents have higher risk still.

The gut-skin axis is the hypothesis that the gut microbiota helps train the developing immune system and that disrupted early-life microbial colonization contributes to allergic disease. Infants who later develop atopy tend to show differences in gut microbiota composition before symptoms appear, including lower diversity and altered ratios of Bifidobacterium, Bacteroides, and certain Lactobacillus species. Early microbial exposure shapes immune tolerance, and probiotic supplementation has been studied as a way to nudge that process. This is the mechanistic frame that motivated the original LGG eczema work. The investigators were not asking whether LGG soothes itchy skin. They were asking whether perinatal exposure to a specific microbe could shift immune development away from the atopic phenotype.

The Kalliomäki Trial: The Central Evidence

The anchor study in this field is a Finnish randomized placebo-controlled trial led by Marko Kalliomäki and Erika Isolauri at the University of Turku. Pregnant women whose families had a history of atopic disease received LGG or placebo for 2 to 4 weeks before delivery, and the infants then received the same intervention for 6 months postnatally, either directly or via breastfeeding. The primary endpoint was atopic eczema at 2 years.

Results were published in the Lancet in 2001. Atopic eczema occurred in 15 of 64 children (23 percent) in the LGG group versus 31 of 68 (46 percent) in placebo, a relative risk of roughly 0.51 [1]. Perinatal LGG was associated with about a 50 percent reduction in eczema at age 2 in this high-risk cohort, with a number needed to treat of approximately 4 to 5. By the standards of allergy prevention trials, that effect size is large.

The same group followed those children. At 4 years, published in the Lancet in 2003, the protective effect persisted: atopic eczema had occurred in 14 of 53 children (26 percent) in the probiotic group versus 25 of 54 (46 percent) in placebo, with the cumulative relative risk around 0.57 [2]. At 7 years, published in the Journal of Allergy and Clinical Immunology in 2007, the cumulative risk of eczema remained significantly lower in the LGG group, although the protective signal for IgE-associated allergic disease as a whole was less clear [3]. Three timepoints, same direction, consistent magnitude. That is unusual in this literature.

The Conflicting Trials: Brouwer and Kopp

The story does not end with Kalliomäki. Several subsequent trials failed to replicate the prevention effect, and at least one trial in established disease found no benefit at all.

Brouwer and colleagues published a Dutch randomized placebo-controlled trial in 2006 in infants who already had atopic dermatitis, randomized to LGG, a different Lactobacillus rhamnosus strain, or placebo in hydrolyzed whey formula. After 3 months they found no significant effect on SCORAD severity, allergic sensitization, or inflammatory markers [4]. The investigators concluded that these probiotics did not provide meaningful benefit for infants with established atopic dermatitis.

Kopp and colleagues published a German randomized double-blind placebo-controlled trial in 2008 in Pediatrics that attempted to replicate Kalliomäki using a similar perinatal LGG protocol in 105 mother-infant pairs with a family history of atopic disease. They found no reduction in atopic dermatitis at 2 years (28 percent in the LGG group versus 27.3 percent in placebo) and noted that recurrent wheezing bronchitis was more common in the probiotic group [5]. Their conclusion was that LGG cannot be generally recommended for primary prevention.

Two well-designed trials, two null results, one a direct attempt to replicate Kalliomäki. Proposed reasons for the discrepancy include differences in baseline maternal and infant microbiota between Finnish and Bavarian populations, dosing schedules, delivery method, and the cohorts' genetic and environmental risk profile. The honest read is that the Kalliomäki effect is real in the population studied but is not guaranteed to transfer to every population or every protocol.

What the Meta-Analyses Say

When trials disagree, meta-analyses become useful. Several have been done here, and they converge on a moderate and statistically significant protective effect for probiotics on infant eczema, with the caveat that certainty of evidence is rated low to moderate and effects vary by strain, timing, and population.

Pelucchi and colleagues published a meta-analysis in Epidemiology in 2012 that included 14 randomized controlled trials. They reported that probiotic supplementation during pregnancy or infancy reduced the incidence of atopic dermatitis with a pooled relative risk of 0.79 (95 percent confidence interval 0.71 to 0.88) [6]. Mansfield and colleagues published a systematic review in Military Medicine in 2014 that included 16 trials and 2,797 participants. They reported a pooled relative risk for eczema of 0.74 (95 percent CI 0.67 to 0.82) and noted that mixed-strain probiotics and certain Lactobacillus strains, including LGG, accounted for most of the protective signal [7]. Cuello-Garcia and colleagues, in the work that informed the World Allergy Organization guidelines, published a systematic review in the Journal of Allergy and Clinical Immunology in 2015 covering 29 randomized trials. They concluded that probiotics used by pregnant women, by breastfeeding mothers, or given directly to infants reduced the risk of eczema, with low certainty of evidence, and no significant effect on other allergic conditions such as asthma or allergic rhinitis [8].

Taken together, the meta-analytic signal is fairly consistent: a roughly 20 to 30 percent relative risk reduction in infant eczema, larger for high-risk infants, smaller or absent in general populations, and concentrated in trials using specific Lactobacillus and Bifidobacterium strains during the perinatal window. LGG is one of the strains that contributes positive signal across these analyses.

Mechanism: What LGG Appears to Do

The mechanistic story for LGG in atopic dermatitis prevention runs along three threads. First, LGG supports T-regulatory cell development. Regulatory T cells are the brake on inflammatory and allergic responses, and their function is partly programmed by signals from gut bacteria. LGG exposure increases IL-10 production and shifts the cytokine balance away from the Th2 dominance that characterizes atopic disease. Second, LGG supports intestinal barrier function. Atopic infants often show increased intestinal permeability, which can allow more food antigens and microbial products to reach immune cells. LGG produces surface molecules and metabolites that interact with intestinal epithelial cells and can tighten barrier function. Third, LGG modulates innate immunity through dendritic cells and pattern recognition receptors, influencing how the broader immune system responds to environmental antigens.

The proposed mechanism is biologically plausible, has experimental support, and aligns with the timing of the clinical effect. The most robust clinical benefit is during the perinatal window, which is when the immune system is most plastic.

Treatment vs Prevention: An Honest Distinction

One of the most important distinctions in this literature is between prevention and treatment. They are not the same question, and the evidence does not run in the same direction.

For primary prevention in high-risk infants, the evidence, while mixed, leans toward a real effect. The Kalliomäki trial and its follow-ups, the Pelucchi, Mansfield, and Cuello-Garcia meta-analyses, and the WAO guideline process all support a protective signal when LGG is given perinatally to families with a history of atopic disease.

For treatment of established atopic dermatitis, the evidence is weaker. The Brouwer trial found no significant benefit. Other trials have produced mixed results: some show modest reductions in SCORAD severity, particularly in children with IgE-associated disease, others do not. Meta-analyses of treatment trials show smaller effect sizes than prevention trials, and atopic dermatitis guidelines do not currently endorse probiotics as a primary treatment.

Practical takeaway: if you are asking whether LGG can help prevent eczema in a high-risk infant, it may help and the downside is small. If you are asking whether it will clear up a toddler's existing eczema, the honest answer is that it might modestly help some children but should not replace standard dermatologic care.

How to Use LGG for Eczema-Prone Families

This is general information. Talk to your pediatrician or dermatologist before starting any probiotic for an infant, a pregnant person, or a child with significant medical history. That matters especially for premature infants, immunocompromised children, and anyone with a central venous catheter, where probiotics carry rare but real risks of bacteremia.

The Kalliomäki protocol gave the mother LGG for the last 2 to 4 weeks of pregnancy and then continued either directly to the infant or via breastfeeding for 6 months postnatally. Doses in the prevention literature generally ranged from 1 to 10 billion CFU per day for infants, and 10 to 20 billion CFU per day for pregnant or breastfeeding mothers. Higher doses are common in adults. The duration that mattered in the trials was the perinatal window plus the first 6 months. There is no evidence that briefly taking a probiotic during a flare produces lasting benefit.

For families with a strong history of atopic disease, the practical question is whether a sustained perinatal LGG regimen is reasonable. The evidence is not conclusive, but it is one of the more replicated probiotic findings in pediatrics, the safety profile is good, and the downside is mostly the cost and the daily routine. For a child who already has atopic dermatitis, LGG is not a substitute for moisturizers, topical anti-inflammatories, trigger identification, and dermatologic care. It may be a complementary tool, especially in children with IgE sensitization. Discuss specifics with your clinician.

Safety Profile

LGG has one of the longest safety records of any probiotic strain, studied in pregnant women, breastfeeding mothers, infants, and children across thousands of trial participants. Serious adverse events are rare. The Kopp trial did note more frequent recurrent wheezing bronchitis in the LGG group, an unexpected finding that has not been clearly replicated.

Known safety concerns concentrate in specific high-risk groups. Premature infants, especially very low birth weight infants, immunocompromised children, children with central venous catheters, and ICU patients have rare reported cases of probiotic bacteremia, including with LGG. These groups should only use probiotics under medical supervision. Healthy term infants, healthy children, and healthy pregnant women have a strong safety record in the published literature.

Wise Choice LGG Probiotic

Our Lactobacillus Rhamnosus GG (LGG) Probiotic Supplement delivers 30 billion CFU per capsule in a 90-capsule bottle. It is the same single strain (Lactobacillus rhamnosus GG, ATCC 53103) used across the prevention and treatment research, including the Kalliomäki trials. We chose this strain because it is one of the few probiotics with decades of strain-specific human evidence rather than category-level mechanism claims. The product is third-party tested and shelf-stable.

For adults supporting gut health, or parents wanting a clinical-strength LGG product to use under pediatric guidance, this is a straightforward option. Capsules can be opened and the contents mixed into a small amount of room-temperature liquid or food for younger children when a clinician advises that approach. Discuss infant and pediatric dosing with your pediatrician.

View the Wise Choice LGG Probiotic for current pricing and full label details.

The Bottom Line

LGG is the most studied single probiotic strain for eczema. The Kalliomäki line of trials, replicated across 2-year, 4-year, and 7-year follow-ups, shows a meaningful reduction in eczema incidence when LGG is given perinatally to high-risk Finnish infants. The Brouwer and Kopp trials show that this effect does not transfer cleanly to every population or protocol, and that LGG does not do much for infants with established atopic dermatitis. Meta-analyses land on a moderate but consistent protective effect for infant eczema, with low to moderate certainty of evidence, concentrated in specific strains given during the perinatal window.

If you are a parent of a high-risk infant considering primary prevention, LGG is one of the most evidence-supported options available, even if the evidence is not airtight. If you are looking for a quick treatment for established eczema, the evidence is weaker. In both cases, talk to your pediatrician or dermatologist, keep using the basic skin care that actually works, and treat probiotics as one possible tool, not a cure.

References

1. Kalliomäki M, Salminen S, Arvilommi H, Kero P, Koskinen P, Isolauri E. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet. 2001;357(9262):1076-9. PMID: 11297958.
2. Kalliomäki M, Salminen S, Poussa T, Arvilommi H, Isolauri E. Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. Lancet. 2003;361(9372):1869-71. PMID: 12788576.
3. Kalliomäki M, Salminen S, Poussa T, Isolauri E. Probiotics during the first 7 years of life: a cumulative risk reduction of eczema in a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2007;119(4):1019-21. PMID: 17289135.
4. Brouwer ML, Wolt-Plompen SA, Dubois AE, et al. No effects of probiotics on atopic dermatitis in infancy: a randomized placebo-controlled trial. Clin Exp Allergy. 2006. PMID: 16839405.
5. Kopp MV, Hennemuth I, Heinzmann A, Urbanek R. Randomized, double-blind, placebo-controlled trial of probiotics for primary prevention: no clinical effects of Lactobacillus GG supplementation. Pediatrics. 2008;121(4):e850-6. PMID: 18332075.
6. Pelucchi C, Chatenoud L, Turati F, et al. Probiotics supplementation during pregnancy or infancy for the prevention of atopic dermatitis: a meta-analysis. Epidemiology. 2012;23(3):402-14. PMID: 22441545.
7. Mansfield JA, Bergin SW, Cooper JR, Olsen CH. Comparative probiotic strain efficacy in the prevention of eczema in infants and children: a systematic review and meta-analysis. Mil Med. 2014;179(6):580-92. PMID: 24902123.
8. Cuello-Garcia CA, Brożek JL, Fiocchi A, et al. Probiotics for the prevention of allergy: A systematic review and meta-analysis of randomized controlled trials. J Allergy Clin Immunol. 2015;136(4):952-61. PMID: 26044853.